Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease

  • Park, Jihye (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Cheon, Jae Hee (Department of Internal Medicine, Yonsei University College of Medicine)
  • Received : 2017.10.21
  • Accepted : 2018.02.26
  • Published : 2018.11.15
⟨ Previous Next ⟩

Abstract

Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor-${\alpha}$, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet's disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor-${\alpha}$ for the treatment of intestinal Behçet's disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet's disease. This review also discusses safety issues associated with anti-tumor necrosis factor-${\alpha}$, including vulnerability to infections and malignancy.

Keywords

References

  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999;341:1284-1291. https://doi.org/10.1056/NEJM199910213411707
  2. James DG. Behcet's syndrome. N Engl J Med 1979;301:431-432. https://doi.org/10.1056/NEJM197908233010811
  3. Nakata K, Murakami T, Hashi N, Tsutsumi S. Neuro-Behcet's syndrome: report of an autopsy case. Bull Osaka Med Sch 1964;10:105-119.
  4. Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease. Curr Opin Rheumatol 2015;27:24-31. https://doi.org/10.1097/BOR.0000000000000125
  5. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet's disease. Inflamm Bowel Dis 2001;7:243-249. https://doi.org/10.1097/00054725-200108000-00010
  6. Park J, Cheon JH, Park YE, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behcet's disease. Int J Colorectal Dis 2017;32:745-751. https://doi.org/10.1007/s00384-016-2728-x
  7. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013;58:496-503. https://doi.org/10.1007/s10620-012-2351-9
  8. Han M, Jung YS, Kim WH, Cheon JH, Park S. Incidence and clinical outcomes of intestinal Behcet's disease in Korea, 2011-2014: a nationwide population-based study. J Gastroenterol 2017;52:920-928. https://doi.org/10.1007/s00535-016-1300-3
  9. Lopalco G, Rigante D, Venerito V, et al. Update on the medical management of gastrointestinal Behcet's disease. Mediators Inflamm 2017;2017:1460491.
  10. Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behcet's disease. Intest Res 2017;15:318-327. https://doi.org/10.5217/ir.2017.15.3.318
  11. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol 2014;49:156-162. https://doi.org/10.1007/s00535-013-0872-4
  12. Goel N, Stephens S. Certolizumab pegol. MAbs 2010;2:137-147. https://doi.org/10.4161/mabs.2.2.11271
  13. Nanke Y, Yago T, Kotake S. The role of Th17 cells in the pathogenesis of Behcet's disease. J Clin Med 2017;6:E74. https://doi.org/10.3390/jcm6070074
  14. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999;42:1967-1974. https://doi.org/10.1002/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z
  15. Gul A. Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(5 Suppl 24):S6-S12.
  16. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNFalpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 2002;11:87-93. https://doi.org/10.1080/09629350220131935
  17. Emmi G, Silvestri E, Bella CD, et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-alpha in early phases of the disease. Medicine (Baltimore) 2016;95:e5516. https://doi.org/10.1097/MD.0000000000005516
  18. Kappen JH, Dik WA, Dingjan GM, et al. Cytokines in the colon of a patient with Behcet's disease. Arthritis Res Ther 2009;11:412. https://doi.org/10.1186/ar2784
  19. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine 2003;24:210-218. https://doi.org/10.1016/j.cyto.2003.09.003
  20. Accardo-Palumbo A, Giardina AR, Ciccia F, et al. Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behcet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther 2010;12:R109. https://doi.org/10.1186/ar3043
  21. Sugita S, Yamada Y, Horie S, et al. Induction of T regulatory cells by cytotoxic T-lymphocyte antigen-2alpha on corneal endothelial cells. Invest Ophthalmol Vis Sci 2011;52:2598-2605. https://doi.org/10.1167/iovs.10-6322
  22. Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther 2012;14:R99. https://doi.org/10.1186/ar3824
  23. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001;120:995-999. https://doi.org/10.1053/gast.2001.22556
  24. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011;21:184-191. https://doi.org/10.3109/s10165-010-0370-y
  25. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013;19:1833-1838.
  26. Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med 2013;52:1855-1862. https://doi.org/10.2169/internalmedicine.52.0589
  27. Ideguchi H, Suda A, Takeno M, et al. Gastrointestinal manifestations of Behcet's disease in Japan: a study of 43 patients. Rheumatol Int 2014;34:851-856. https://doi.org/10.1007/s00296-013-2838-5
  28. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun 2015;62:67-74. https://doi.org/10.1016/j.jaut.2015.06.005
  29. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. https://doi.org/10.1097/MD.0000000000003863
  30. Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet's disease treated with infliximab. Dig Dis Sci 2017;62:441-447. https://doi.org/10.1007/s10620-016-4395-8
  31. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-728. https://doi.org/10.1136/gut.49.5.725
  32. Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46:118-121. https://doi.org/10.1007/s10350-004-6506-4
  33. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-27. https://doi.org/10.3904/kjim.2007.22.1.24
  34. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behcet's disease: report of a case. Dis Colon Rectum 2007;50:672-676. https://doi.org/10.1007/s10350-006-0813-x
  35. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behcet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008;46:212-215. https://doi.org/10.1097/MPG.0b013e3181346b60
  36. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008;14:1259-1264. https://doi.org/10.1002/ibd.20457
  37. Maruyama Y, Hisamatsu T, Matsuoka K, et al. A case of intestinal Behcet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012;51:2125-2129. https://doi.org/10.2169/internalmedicine.51.8005
  38. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis 2011;17:605-613. https://doi.org/10.1002/ibd.21313
  39. Park J, Cheon JH. Could adalimumab be used safely and effectively in intestinal Behcet's disease refractory to conventional therapy? Intest Res 2017;15:263-265. https://doi.org/10.5217/ir.2017.15.3.263
  40. Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2017;32:769-777. https://doi.org/10.1111/jgh.13612
  41. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015;13:940-948.e3. https://doi.org/10.1016/j.cgh.2014.08.042
  42. Tanida S, Mizoshita T, Nishie H, et al. Long-term efficacy of adalimumab in patients with intestinal Behcet's disease: eight consecutive cases. J Clin Med Res 2016;8:334-337. https://doi.org/10.14740/jocmr2477w
  43. Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res 2017;15:395-401. https://doi.org/10.5217/ir.2017.15.3.395
  44. Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behcet's disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 2017;36:451-455. https://doi.org/10.1007/s10067-016-3417-4
  45. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007;66:565-566.
  46. De Cassan C, De Vroey B, Dussault C, Hachulla E, Buche S, Colombel JF. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. J Crohns Colitis 2011;5:364-368. https://doi.org/10.1016/j.crohns.2011.03.006
  47. Toyonaga T, Nakase H, Matsuura M, et al. Refractoriness of intestinal Behcet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies: our case experience and review of the literature. Digestion 2013;88:217-221. https://doi.org/10.1159/000355341
  48. Kimura M, Tsuji Y, Iwai M, et al. Usefulness of adalimumab for treating a case of intestinal Behcet's disease with trisomy 8 myelodysplastic syndrome. Intest Res 2015;13:166-169. https://doi.org/10.5217/ir.2015.13.2.166
  49. Mizoshita T, Tanida S, Joh T. Adalimumab treatment in intestinal Behcet's disease: relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement. Dig Liver Dis 2015;47:991-992. https://doi.org/10.1016/j.dld.2015.07.007
  50. Smola MG, Soyer HP, Scharnagl E. Surgical treatment of dermatofibrosarcoma protuberans: a retrospective study of 20 cases with review of literature. Eur J Surg Oncol 1991;17:447-453.
  51. Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet's disease. Cell Biochem Biophys 2014;69:735-739. https://doi.org/10.1007/s12013-014-9860-4
  52. Vitale A, Emmi G, Lopalco G, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behcet's disease. Clin Rheumatol 2017;36:2063-2069. https://doi.org/10.1007/s10067-017-3627-4
  53. Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab pegol treatment in Behcet's disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol 2017;27:1031-1035. https://doi.org/10.1080/14397595.2017.1285857
  54. Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H. A young girl with refractory intestinal Behcet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int 2013;33:3105-3108. https://doi.org/10.1007/s00296-012-2628-5
  55. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105.
  56. Curigliano V, Giovinale M, Fonnesu C, et al. Efficacy of etanercept in the treatment of a patient with Behcet's disease. Clin Rheumatol 2008;27:933-936. https://doi.org/10.1007/s10067-008-0857-5
  57. Mohammed RH. Etanercept therapy in Behcet's disease: the tight control strategy in refractory disease. Z Rheumatol 2014;73:650-656. https://doi.org/10.1007/s00393-013-1307-6
  58. Iriarte A, Zaera C, Bachiller-Corral J, Lopez-Sanroman A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol 2017;40:117-121. https://doi.org/10.1016/j.gastrohep.2016.01.011
  59. Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49:1694-1698. https://doi.org/10.1093/rheumatology/keq136
  60. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-647. https://doi.org/10.1002/art.22669
  61. Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008;10:393-406.
  62. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108:1835-1842. https://doi.org/10.1038/ajg.2013.294
  63. Bewtra M. Lymphoma in inflammatory bowel disease and treatment decisions. Am J Gastroenterol 2012;107:964-970. https://doi.org/10.1038/ajg.2011.479
  64. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-881. https://doi.org/10.1016/j.cgh.2009.01.004
  65. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268-274. https://doi.org/10.1016/j.cgh.2009.11.024
  66. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014;8:31-44. https://doi.org/10.1016/j.crohns.2013.04.006
  67. Stubiger N. Behcet's disease. Epidemiology, clinical manifestations, immunology and therapy. Ophthalmologe 2012;109:529-530. https://doi.org/10.1007/s00347-011-2505-8
  68. Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis 2017;11:954-962. https://doi.org/10.1093/ecco-jcc/jjx040
  69. Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behcet's disease. Clin J Gastroenterol 2014;7:205-212. https://doi.org/10.1007/s12328-014-0488-0
  70. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximaband immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-1063. https://doi.org/10.1038/ajg.2012.89
  71. Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol 2015;50:312-320. https://doi.org/10.3109/00365521.2014.1000960
  72. Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis 2014;8:282-287. https://doi.org/10.1016/j.crohns.2013.08.017
  73. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012;18:750-757. https://doi.org/10.1002/ibd.21757

Cited by

  1. Behçet’s Disease in Children: Diagnostic and Management Challenges vol.16, pp.None, 2018, https://doi.org/10.2147/tcrm.s232660
  2. Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease vol.79, pp.7, 2018, https://doi.org/10.1007/s00393-020-00816-0
  3. Vasculitis, Autoimmunity, and Cytokines: How the Immune System Can Harm the Brain vol.18, pp.11, 2018, https://doi.org/10.3390/ijerph18115585
  4. Behcet’s Disease: An In-Depth Review about Pathogenesis, Gastrointestinal Manifestations, and Management vol.6, pp.4, 2018, https://doi.org/10.1159/000520696